相关实验视频

Updated: Jun 25, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

在甲状腺 papillary carcinoma 需要年龄和性别匹配的术后治疗

Caigu Yan¹, Jinjin Sun¹, Xianghui He²

¹Department of General Surgery, The Second Hospital of Tianjin Medical University, Tianjin, China.

Frontiers in endocrinology

|July 8, 2024

概括

甲状腺乳腺癌的复发与淋巴结转移有关. 这项研究确定了风险因素和SLC5A5基因,建议根据性别和年龄进行个性化术后治疗.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
基因组学就是基因组学.

背景情况:

甲状腺乳头癌 (PTC) 经常在手术后复发,需要有效的术后疗法,如TSH抑制和放射性 (I).
了解PTC中淋巴结转移 (LNM) 的机制对于开发向治疗至关重要.

研究的目的:

调查在PTC中与LNM相关的临床风险因素.
探索分子机制,包括基因表达模式,是 PTC 中 LNM 的基础.
确定潜在的生物标志物来预测PTC复发和指导治疗策略.

主要方法:

对2073名PTC患者的临床数据进行分析,以确定LNM风险因素.
利用癌症基因组图谱甲状腺癌 (TCGA-THCA) 和基因表达总汇 (GEO) 数据库进行基因表达分析.
采用单细胞RNA测序 (scRNA-seq) 在颗粒层面检查基因表达.

主要成果:

男性性别,年轻年龄,较大的瘤大小和甲状腺外延伸 (ETE) 是LNM (P<0.05) 的重要危险因素.
甲状腺功能参数 (TSH,FT3,FT4) 与LNM没有相关性 (P>0.05).
发现SLC5A5基因在男性,年轻患者和LNM患者中是下调的,其较低的表达与较差的无疾病存活率相关. 在瘤和淋巴结转移样本中,SLC5A5表达减少,与TSHR表达呈正相关性.

结论:

术后治疗PTC应该是个性化的,考虑到性别和年龄的特殊差异.
在特定患者群体中SLC5A5的下调表明它在PTC进展和转移中的作用.
对TSH-SLC5A5-TSHR轴的进一步研究可能会揭示PTC的新治疗点.

关键词:

第131章一百三十一章在SLC5A5A5A5A5A5A5A5A5A5A5 在 TSH 中,您可以使用淋巴结转移是淋巴结的转移.皮囊甲状腺癌是甲状腺癌.

更多相关视频

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

相关概念视频

Synthesis and Regulation of Thyroid Hormones

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...